Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after market hours. Here’s what you need to know.

Supernus Pharmaceuticals beat analysts’ revenue expectations by 16.9% last quarter, reporting revenues of $175.7 million, up 14.2% year on year. It was an incredible quarter for the company, with an impressive beat of analysts’ EPS estimates and full-year operating income guidance exceeding analysts’ expectations.

Is Supernus Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Supernus Pharmaceuticals’s revenue to decline 5.5% year on year to $155.2 million, a further deceleration from the 1.8% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.52 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Supernus Pharmaceuticals has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Supernus Pharmaceuticals’s peers in the branded pharmaceuticals segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Pfizer delivered year-on-year revenue growth of 21.9%, beating analysts’ expectations by 3%, and Eli Lilly reported revenues up 44.7%, in line with consensus estimates. Pfizer’s stock price was unchanged after the results, while Eli Lilly was up 4.2%.

Read our full analysis of Pfizer’s results here and Eli Lilly’s results here.

Stocks generally had a good 2024. The Fed fought high inflation and won without sending the economy into a recession, otherwise lovingly known as a soft landing. The US Central Bank is now cutting rates. That, plus the election of Donald Trump in November 2024, sent markets even higher, and while some of the branded pharmaceuticals stocks have shown solid performance, the group has generally underperformed, with share prices down 5.3% on average over the last month. Supernus Pharmaceuticals is down 17.3% during the same time and is heading into earnings with an average analyst price target of $38.80 (compared to the current share price of $32.60).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.